Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06377930 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy

A Phase 2 study of Focal Onset Seizures, sponsored by Rapport Therapeutics.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target
12
Study locations

NCT06377930 is a Phase 2 study of Focal Onset Seizures that has completed, run by Rapport Therapeutics. The registered enrollment target is 30 participants, below the 275-participant average among 4 other Focal Onset Seizures trials with a reported enrollment target (89% lower). The trial reports 12 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06377930, a Phase 2 study of Focal Onset Seizures, has completed, sponsored by Rapport Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target
12
Study locations

Study Summary

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.

Conditions Studied

Focal Onset Seizures

Interventions

  • DRUG RAP-219

Study Locations (12)

Pennsylvania

  • University of Pennsylvania - Department of Neurology - Philadelphia
  • Thomas Jefferson University - Philadelphia

Texas

  • Baylor College of Medicine - Houston
  • University of Texas Health Science Center, Houston - Houston

Connecticut

  • Yale University - New Haven

Idaho

  • Consultants in Epilepsy and Neurology, PLLC - Boise

Indiana

  • IU Health Neuroscience Center, Goodman Hall - Indianapolis

Kansas

  • The University of Kansas Medical Center Epilepsy Clinic - Kansas City

Minnesota

  • Mayo Clinic - Rochester

New York

  • NYU Langone Comprehensive Epilepsy Center - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-10-10
Est. Completion 2025-09-26
Phase Phase 2

Sponsor

Rapport Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06377930

The ClinicalTrials.gov registry entry for NCT06377930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 275-participant average among 4 other Focal Onset Seizures trials with a reported enrollment target (89% lower). The listed sponsor is Rapport Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Focal Onset Seizures appearing as the primary indexed condition, and to 1 intervention - of which RAP-219 is the first listed.

NCT06377930 reports 12 study locations spanning 10 distinct geographic areas - top geographies include Pennsylvania, Texas, Connecticut.

Frequently Asked Questions

What is clinical trial NCT06377930 about?

NCT06377930 is a clinical study titled "Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy". This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine if RAP-219 works and is safe in patients with Refractory Focal Epilepsy.

What is the current status of trial NCT06377930?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2024-10-10. Estimated completion is 2025-09-26.

What conditions does trial NCT06377930 study?

This clinical trial studies the following conditions: Focal Onset Seizures.

What interventions are being tested in trial NCT06377930?

The interventions under investigation include: RAP-219 (DRUG).

Who is sponsoring clinical trial NCT06377930?

This trial is sponsored by Rapport Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06377930 being conducted?

This trial has 12 study locations across Connecticut, Idaho, Indiana, Kansas, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Focal Onset Seizures

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Focal Onset Seizures

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.